Selvax is a preclinical stage company developing a safe, effective, immunological-based treatment for a range of hard to treat solid tumours. It was established in 2015 from research at Curtin University that achieved a major breakthrough in the treatment of cancer by harnessing and amplifying the body’s anti-tumour immune response. Our lead candidate combines two immunological agents, which are administered directly into the tumour site causing regression of solid tumours (including chemotherapy-resistant) with minimal toxic side effects. The complete tumour clearance rates achieved in small animal models with eight different solid tumours ranged from 90% for colorectal cancer to 30% for renal cancers. Data showed no tumour recurrence for the life of the animal and clearance of a second tumour in another part of the body (abscopal metastatic model). An animal health product also being developed for treating dogs with cancer has achieved positive results in a trial conducted in collaboration with Perth Veterinary Specialists, a specialist oncology clinic. The Selvax approach differs from standard chemotherapy and radiological treatments in that its goal is to stimulate the patient’s own immune system to kill the cancer. The treatment effectively acts as a 'vaccine' against recurrence of the cancer.